AmideBio has leveraged its core BioPure™ technology to pursue a series of therapeutic targets that include, ultrastable and ultraconcentrated insulin for T2 diabetes, glucose responsive insulin for T1 and T2 diabetes, solution stable glucagon for hyperinsulinism and similar orphan indications for which orphan drug designation (ODD) and/or rare pediatric disease designation (RPDD) are applicable.  The company is also pursuing the development of diagnostics for early detection of T1 diabetes. The key to these discovery programs is theBioPure™ process which allows rapid candidate peptide production for QSAR studies.

PROGRAM

INDICATION

DISCOVERY            PRECLINICAL           IND ENABLING          PHASE 1

ULTRASTABLE INSULIN

LEAD AB-U177

T1 DIABETES
SOLUTION STABLE GLUCAGON

LEAD AB-G023

HYPERINSULINISM
ODD granted

GLUCOSE RESPONSIVE INSULIN

LEAD AB-R084

T1/T2 DIABETES
UNDISCLOSED

LEAD AB-L045

UNDISCLOSED
T1 DIAGNOSTIC

LEAD AB-D014

T1 DIABETES